Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Eli Lilly and Company
Actuate Therapeutics Inc.
Memorial Sloan Kettering Cancer Center
Centre Oscar Lambret
QBiotics Group Limited
M.D. Anderson Cancer Center
Hackensack Meridian Health
Rutgers, The State University of New Jersey
UNICANCER
Memorial Sloan Kettering Cancer Center
Institut Bergonié
Institut Bergonié
Institut Bergonié
Stony Brook University
Elevation Oncology
Radboud University Medical Center
Astex Pharmaceuticals, Inc.
ImmunityBio, Inc.
Memorial Sloan Kettering Cancer Center
pharmaand GmbH
University Health Network, Toronto
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Eastern Cooperative Oncology Group
Grupo Espanol de Investigacion en Sarcomas
Grupo Espanol de Investigacion en Sarcomas
Amgen
Institut Bergonié
Grupo Espanol de Investigacion en Sarcomas
Northwestern University
UNICANCER
Heidelberg University
NYU Langone Health
Hoffmann-La Roche
Massachusetts General Hospital
MabVax Therapeutics, Inc.
Grupo de Apoio ao Adolescente e a Crianca com Cancer
National Institutes of Health Clinical Center (CC)
InSightec
University of Michigan Rogel Cancer Center
Children's Oncology Group
Merck Sharp & Dohme LLC
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hoffmann-La Roche
Rocky Mountain Cancer Centers
Enzon Pharmaceuticals, Inc.
City of Hope Medical Center
Mayo Clinic
Maisonneuve-Rosemont Hospital